| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ramaswamy Govindan | |
| P2860 | cites work | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 |
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 | ||
| Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants | Q24810573 | ||
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies | Q27851393 | ||
| Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions | Q28609149 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib | Q33821320 | ||
| Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
| Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 | ||
| Epidermal growth factor receptor family in lung cancer and premalignancy | Q34563679 | ||
| Update on epidermal growth factor receptor mutations in non-small cell lung cancer | Q34594740 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| The epidermal growth factor receptor family | Q36236606 | ||
| Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance | Q36445820 | ||
| HKI-272 in non small cell lung cancer. | Q36899870 | ||
| Structure and clinical relevance of the epidermal growth factor receptor in human cancer | Q37122918 | ||
| Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor | Q40077599 | ||
| Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. | Q40216149 | ||
| Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. | Q40259915 | ||
| HER2/neu expression in malignant lung tumors | Q40653428 | ||
| ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 | ||
| Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts | Q42797529 | ||
| Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. | Q46004116 | ||
| Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients | Q46624747 | ||
| EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib | Q46858893 | ||
| Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer | Q47252774 | ||
| Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. | Q53554133 | ||
| Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma | Q72784859 | ||
| Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer | Q79317427 | ||
| Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors | Q80315104 | ||
| Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors | Q83367527 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | Chinese | Q7850 |
| P304 | page(s) | 363-369 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Chinese Journal of Lung Cancer | Q26842043 |
| P1476 | title | [A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]. | |
| P478 | volume | 13 |
Search more.